Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 1,564 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Regimen Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Case Selection and Treatment Protocol for Immediate Dental Implants in the Esthetic Zone

NCT02154581
View directory record Official record
Conditions
Jaw, Edentulous, Partially, Acquired Absence of Single Tooth
Interventions
SLActive implant
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

NCT01845831
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Phase 1Phase 2 Interventional Results available

AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin

NCT00147225
View directory record Official record
Conditions
Solid Tumors, Advanced Cancer
Interventions
AMG 531, Carboplatin, Adriamycin, Ifosfamide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants

NCT02943746
View directory record Official record
Conditions
Premature Infants
Interventions
Standard Protein Diet, High Protein Diet
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
14 Days and older
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Phase 4 Interventional Results available

Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo

NCT02957682
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Praluent (Alirocumab), Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
73
States / cities
Auburn, Alabama • Birmingham, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated May 7, 2021 · Synced Oct 26, 2026, 2:13 AM EDT
Enrolling by invitation Phase 2 Interventional

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

NCT06275620
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
AGTC-501 (high dose and standard corticosteroid regimen), AGTC-501 (low dose and standard corticosteroid regimen), AGTC-501 (high dose and modified corticosteroid regimen)
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
12 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
7
States / cities
Jacksonville, Florida • Miami, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

The Effects of a Novel Probiotic Supplement on Menopausal Symptoms and Bone Health

NCT04001088
View directory record Official record
Conditions
Menopause
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Lallemand Health Solutions
Industry
Eligibility
40 Years to 59 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
5
States / cities
Lake Worth, Florida • Port Saint Lucie, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 26, 2026, 2:13 AM EDT
Recruiting Not applicable Interventional

MindWalk Intervention for Older South Asian Caregivers of People With Cognitive Disabilities (CD)

NCT06002919
View directory record Official record
Conditions
Stress, Psychological, Cognitive Decline
Interventions
MindWalk Intervention
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
45 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Bolingbrook, Illinois • Buffalo Grove, Illinois • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 26, 2026, 2:13 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)

NCT02082522
View directory record Official record
Conditions
Hilar Cholangiocarcinoma
Interventions
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen
Drug · Procedure
Lead sponsor
Concordia Laboratories Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 26, 2026, 2:13 AM EDT
Terminated Phase 4 Interventional Results available

Simplified Insulin Regimen for the Elderly

NCT03660553
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Glargine, Insulin Aspart, Insulin Lispro
Drug
Lead sponsor
University of Miami
Other
Eligibility
65 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Results available

A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

NCT03533114
View directory record Official record
Conditions
Idiopathic Hypersomnia
Interventions
JZP-258, Placebo Oral Solution
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
40
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

NCT00466440
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzastaurin, placebo, docetaxel, prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 26, 2026, 2:13 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis

NCT06506916
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Fountain Valley, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

NCT05585606
View directory record Official record
Conditions
Acute Ischemic Stroke (AIS)
Interventions
Placebo, scp776 (1.9 mg/kg), scp776 (3.8 mg/kg), scp776 (4.8 mg/kg), scp776 (all dose levels)
Drug
Lead sponsor
Silver Creek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Scottsdale, Arizona • Tucson, Arizona • Hartford, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Results available

Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)

NCT00102804
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Pemetrexed, Placebo, Best Supportive Care
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
6
States / cities
Minneapolis, Minnesota • Portsmouth, New Hampshire • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Not applicable Interventional Results available

Antibody Response to Human Papillomavirus Recombinant Vaccine (Gardasil®) in Girls and Young Women With Chronic Kidney Disease

NCT00806676
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Gardasil® Vaccine (FDA-approved vaccination regimen)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
9 Years to 21 Years · Female only
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

NCT00004985
View directory record Official record
Conditions
HIV Infections
Interventions
Capravirine, Nelfinavir mesylate
Drug
Lead sponsor
Agouron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
33
States / cities
Phoenix, Arizona • Beverly Hills, California • Palm Springs, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 26, 2026, 2:13 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant

NCT05948540
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Intervention C Daridorexant, Intervention C Placebo
Drug
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
9
States / cities
Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Not applicable Interventional

Feasibility of Action Observation and Repetitive Task Practice on Upper Extremity Outcomes in Chronic Stroke Survivors

NCT04015271
View directory record Official record
Conditions
Stroke, Hemiparesis
Interventions
Action Observation + Repetitive Task Practice, Placebo Video + Repetitive Task Practice
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite

NCT04996264
View directory record Official record
Conditions
Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
Interventions
Varespladib Methyl, Placebo, Standard of care (SOC)
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
5 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Tucson, Arizona • Loma Linda, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

NCT04944992
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Interventions
Efinopegdutide 20 mg/mL, Semaglutide 1.34 mg/mL
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Montclair, California • Hialeah, Florida • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2023 · Synced Oct 26, 2026, 2:13 AM EDT
Terminated Phase 1 Interventional

Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users

NCT03059563
View directory record Official record
Conditions
Dopamine D2/3 Receptor Availability, Cognitive Function, Methamphetamine Abuse
Interventions
Varenicline, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 26, 2026, 2:13 AM EDT
Terminated Not applicable Interventional Results available

Prospective Treatment Study of Catatonia Patients

NCT02734498
View directory record Official record
Conditions
Catatonia
Interventions
Electroconvulsive Treatment (ECT) Right Unilateral, Electroconvulsive Treatment (ECT) - Bilateral
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2019 · Synced Oct 26, 2026, 2:13 AM EDT
Completed Not applicable Interventional

Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN)

NCT00708981
View directory record Official record
Conditions
Diabetic Nephropathy
Interventions
Multifactorial Intervention
Other
Lead sponsor
Cook County Health
Government
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 26, 2026, 2:13 AM EDT